Is Breast Cancer Survival Improving? Trends in Survival for Patients with Recurrent Breast Cancer Diagnosed from 1974 through 2000

Cancer

Volumn 100, Issue 1, 2004, Pages 44-52

  Giordano, Sharon H ^a   Buzdar, Aman U ^a   Smith, Terry L ^a   Kau, Shu Wan ^a   Yang, Ying ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Prognostic factors; Recurrence; Survival

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; FLUOXYMESTERONE; GEMCITABINE; GOSERELIN; LETROZOLE; LEUPRORELIN; MEGESTROL ACETATE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; TAMOXIFEN; TAXANE DERIVATIVE; TOREMIFENE; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0346847742     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11859     Document Type: Article

References (19)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405-410.
3. Fisher B, Carbone P, Economou SG, et al. 1-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975;292:117-122.
4. Anonymous. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1988;319:1681-1692.
5. Anonymous. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;352:930-942.
6. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983.
7. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999;17:1413-1424.
8. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
9. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol. 2002;20:2812-2823.
10. Buzdar AU, Blumenschein GR, Gutterman JU, et al. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. JAMA. 1979;242:1509-1513.
11. Buzdar AU, Blumenschein GR, Smith TL, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer. 1984;53:384-389.
12. Buzdar AU, Hortobagyi GN, Smith TL, et al. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 1988;62:2098-2104.
13. Buzdar AU, Hortobagyi GN, Kau SW, et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for Stage II or III breast cancer. J Clin Oncol. 1992;10:1540-1546.
14. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of Stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995;4:715-734.
15. Assikis V, Buzdar A, Yang Y, et al. A Phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003;97:2716-2723.
16. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187-220.
17. Clark GM, Sledge GW Jr., Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987;5:55-61.
18. Chia SK, Speers C, Kang A, et al. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer in a population based cohort [abstract]. Proc Am Soc Clin Oncol. 2003;22:22a.
19. Arveux P, Grosclaude P, Reyrat E, Velten M, Bardau V, Borella L. Breast cancer survival in France: a relative survival analysis based on 68,449 cases treated in the 20 French comprehensive cancer centers between 1980 and 1999 [abstract]. Proc Am Soc Clin Oncol. 2003;22:3437a.